Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share incentive awards

10 Jun 2022 07:00

RNS Number : 4084O
Omega Diagnostics Group PLC
10 June 2022
 

OMEGA DIAGNOSTICS GROUP PLC

 

("Omega" or the "Company" or the "Group")

 

 

Grant of share incentive awards to Directors and senior managers

 

1. Establishment and operation of the Company's new Long Term Incentive Plan

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that, on 8 June 2022, it granted awards ("Awards") over ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") to Executive Directors pursuant to the terms of its newly established Long Term Incentive Plan (the "LTIP"), details of which are set out below:

 

Director

Board Position

Number of Ordinary Shares over which "Performance Awards" granted

Number of Ordinary Shares over which "Retention Awards" granted

Total number of Ordinary Shares over which Awards granted

Jag Grewal

CEO

4,700,715

1,200,000

5,900,715

Chris Lea

CFO

4,339,121

1,000,000

5,339,121

 

The LTIP has been established in order to incentivise Executive Directors and certain senior managers to deliver long term value for shareholders, align their interests with the various stakeholders and retain these key individuals within the business. No consideration was paid for the grant of the Awards, which have been structured as "nil cost" options.

 

The Performance Awards detailed in the above table will normally vest on the third anniversary of grant but only if, at that time, the Company's share price (averaged over a 90day period) is equal to or greater than 12 pence per Ordinary Share. Vesting will normally be dependent on the continued employment of the participant within the Group.

 

The vesting of the Retention Awards is dependent solely on continued employment over the period of three years from grant (or, in the case of Chris Lea, the period of three years from 30 August 2021, being the date on which he was originally appointed as an Executive Director).

 

Once the Awards have vested, they will generally be available to be exercised until the tenth anniversary of their original grant.

 

In addition, Awards over an aggregate of 3,000,000 Ordinary Shares were also granted on 8 June 2022 to certain other senior managers in the business. These Awards are all Performance Awards with the same vesting criteria as detailed above.

 

Further information in relation to the LTIP will be included in Omega's next annual report and financial statements.

 

2. Grant of stand-alone option to Chairman

 

Omega also announces that, on 9 June 2022, it granted the following conditional option over Ordinary Shares (with an exercise price of 4 pence per share) to the Company's Chairman:

 

Director

Board Position

Number of Ordinary Shares over which conditional option granted

Simon Douglas

Non-Executive Chairman

200,000

 

The terms of the above option are set out in a stand-alone agreement entered into between the Company and Simon Douglas. Subject to continued appointment as a Director, it will normally vest and become exercisable on the third anniversary of its grant. For the avoidance of doubt, no consideration was paid for the grant of this option.

 

 

3. Release of previous options

 

In advance of the grant of the Awards and options detailed above, both Jag Grewal and Simon Douglas released all existing rights to acquire Ordinary Shares that had previously been granted to them under Omega's various share incentive arrangements.

 

4. Overview of options held by Omega's Directors

 

Following the transactions described above, the position of those directors being granted options can be summarised as follows:

 

Director

Board Position

 

 

Ordinary shares held

Previous number of Ordinary Shares subject to Awards / options

Current number of Ordinary Shares subject to Awards / options

Combined interest of equity held and options as a percentage of issued share capital

Simon Douglas

Non-Executive Chairman

 

500,000

200,000

200,000

 

0.3%

Jag Grewal

CEO

 

735,746

1,200,000

5,900,715

 

2.8%

Chris Lea

CFO

 

500,000

0

5,339,121

 

2.4%

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

 

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/ Harriet Ward (ECM)

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Jag Grewal

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Omega Diagnostics Group PLC

b)

 

LEI

 

2138007U9P4BTZTYIR92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Grant of "Retention Award" (in the form of a nil cost option) over Ordinary Shares pursuant to the Omega Diagnostics Group PLC Long Term Incentive Plan

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil (exercise price)

1,200,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

8 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Grant of "Performance Award" (in the form of a nil cost option) over Ordinary Shares pursuant to the Omega Diagnostics Group PLC Long Term Incentive Plan

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil (exercise price)

4,700,715

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

8 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Release of option over Ordinary Shares originally granted on 5 July 2012 pursuant to the Omega Diagnostics Group PLC EMI Option Scheme

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

14.5p (exercise price)

90,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

7 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Release of option over Ordinary Shares originally granted on 25 February 2014 pursuant to the Omega Diagnostics Group PLC EMI Option Scheme

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

30.5p (exercise price)

610,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

7 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Release of option over Ordinary Shares originally granted on 23 January 2020 pursuant to the Omega EMI Plan 2020

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

15.4p (exercise price)

500,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

7 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Chris Lea

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Omega Diagnostics Group PLC

b)

 

LEI

 

2138007U9P4BTZTYIR92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Grant of "Retention Award" (in the form of a nil cost option) over Ordinary Shares pursuant to the Omega Diagnostics Group PLC Long Term Incentive Plan

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil (exercise price)

1,000,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

8 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Grant of "Performance Award" (in the form of a nil cost option) over Ordinary Shares pursuant to the Omega Diagnostics Group PLC Long Term Incentive Plan

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil (exercise price)

4,339,121

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

8 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Simon Douglas

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Omega Diagnostics Group PLC

b)

 

LEI

 

2138007U9P4BTZTYIR92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Grant of option over Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

4p (exercise price)

200,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

9 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each ("Ordinary Shares") 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Release of option over Ordinary Shares originally granted on 5 March 2021 pursuant to the Omega Diagnostics Group PLC Third Unapproved Option Scheme

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

89p (exercise price)

200,000

d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

Not applicable

e)

 

Date of the transaction

 

8 June 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUKRORUVUNRUR
Date   Source Headline
6th Sep 20237:00 amRNSAGM Statement
1st Sep 202310:29 amRNSUpdate on proposed Share Reorganisation
31st Aug 20237:00 amRNSProposed Share Reorganisation Timetable
22nd Aug 20237:00 amRNSDirectorate Change
17th Aug 20237:00 amRNSBoard Appointment
15th Aug 20231:45 pmRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSPosting of Annual Report and confirmation of AGM
3rd Aug 20237:00 amRNSFinal Results
27th Jul 20237:00 amRNSNotice of Results
26th Jul 20232:10 pmRNSHolding(s) in Company
6th Jun 202311:19 amRNSHolding(s) in Company
5th Jun 20234:51 pmRNSHolding(s) in Company
2nd Jun 20232:45 pmRNSHolding(s) in Company
22nd May 20235:33 pmRNSHolding(s) in Company
10th May 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
9th May 20233:42 pmRNSDirector/PDMR Shareholding
21st Apr 20239:48 amRNSHolding(s) in Company
19th Apr 20239:31 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSTrading Update
22nd Mar 20235:57 pmRNSBlock Listing Six Monthly Return
22nd Mar 20233:00 pmRNSHolding(s) in Company
6th Mar 20232:31 pmRNSHolding(s) in Company
27th Jan 20233:03 pmRNSHolding(s) in Company
27th Jan 20239:36 amRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSTrading update
16th Jan 202310:56 amRNSHolding(s) in Company
6th Jan 20237:00 amRNSUS expansion update
3rd Jan 202312:34 pmRNSHolding(s) in Company
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 202212:01 pmRNSHolding(s) in Company
30th Nov 20229:35 amRNSHolding(s) in Company
25th Nov 20227:00 amRNSReceipt of deferred consideration
24th Nov 20227:00 amRNSHalf-year Report
23rd Nov 20224:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20222:05 pmRNSSecond Price Monitoring Extn
23rd Nov 20222:00 pmRNSPrice Monitoring Extension
18th Nov 202212:09 pmRNSHolding(s) in Company
16th Nov 20222:06 pmRNSSecond Price Monitoring Extn
16th Nov 20222:00 pmRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSConfirmation of Results and Investor Presentation
14th Nov 20227:00 amRNSPartnership agreement with Software Provider
8th Nov 20229:04 amRNSLaunch of new all-employee share incentive plan
26th Oct 20222:50 pmRNSResult of AGM
26th Oct 20227:00 amRNSAGM Statement and Notice of Results
11th Oct 20227:00 amRNSScientific Director to present at FIDHC
5th Oct 20227:00 amRNSPositive WHO data received for VISITECT® CD4 test
27th Sep 20227:00 amRNSPosting of Annual Report and confirmation of AGM
20th Sep 202212:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.